Total Payments
$99,066
2024 Payments
$42,627
Companies
20
Transactions
101
Medicare Patients
1,064
Medicare Billing
$201,326
Payment Breakdown by Category
Consulting$85,354 (86.2%)
Other$5,750 (5.8%)
Travel$4,465 (4.5%)
Food & Beverage$3,409 (3.4%)
Education$89.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $85,354 | 25 | 86.2% |
| Honoraria | $5,000 | 2 | 5.0% |
| Travel and Lodging | $4,465 | 22 | 4.5% |
| Food and Beverage | $3,409 | 50 | 3.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $750.00 | 1 | 0.8% |
| Education | $89.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $39,638 | 25 | $0 (2024) |
| Kite Pharma, Inc. | $37,060 | 34 | $0 (2024) |
| Genmab U.S., Inc. | $4,308 | 12 | $0 (2024) |
| ABBVIE INC. | $4,050 | 1 | $0 (2022) |
| Seagen Inc. | $3,575 | 2 | $0 (2021) |
| Adaptive Biotechnologies Corporation | $3,090 | 2 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $2,483 | 4 | $0 (2024) |
| SANOFI US SERVICES INC. | $2,157 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $1,395 | 2 | $0 (2023) |
| Celgene Corporation | $395.05 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,627 | 48 | Kite Pharma, Inc. ($26,666) |
| 2023 | $23,877 | 26 | ADC Therapeutics America, Inc. ($18,815) |
| 2022 | $21,182 | 14 | ADC Therapeutics America, Inc. ($11,760) |
| 2021 | $4,871 | 4 | SANOFI US SERVICES INC. ($2,157) |
| 2020 | $2,333 | 3 | Seagen Inc. ($2,200) |
| 2019 | $3,866 | 3 | Adaptive Biotechnologies Corporation ($3,000) |
| 2017 | $311.07 | 3 | Astellas Pharma US Inc ($196.84) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Genmab U.S., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,140.00 | General |
| 12/10/2024 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $181.26 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $75.10 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $46.48 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $42.59 | General |
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $29.00 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $17.99 | General |
| Category: CELLT | ||||||
| 12/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $8.95 | General |
| Category: CELLT | ||||||
| 11/14/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $10,450.00 | General |
| Category: CELLT | ||||||
| 11/09/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $300.52 | General |
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CELLT | ||||||
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CELLT | ||||||
| 11/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: CELLT | ||||||
| 11/08/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $55.20 | General |
| 11/08/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $47.94 | General |
| 11/08/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $41.10 | General |
| 11/08/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $29.00 | General |
| 11/08/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $28.19 | General |
| 11/08/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $28.19 | General |
| 10/31/2024 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| 10/21/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $539.97 | General |
| 10/21/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $40.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 288 | 600 | $200,685 | $55,719 |
| 2022 | 8 | 282 | 578 | $188,752 | $52,493 |
| 2021 | 6 | 202 | 447 | $144,987 | $41,132 |
| 2020 | 7 | 292 | 773 | $183,751 | $51,981 |
Total Patients
1,064
Total Services
2,398
Medicare Billing
$201,326
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 57 | 264 | $74,992 | $24,767 | 33.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 51 | 108 | $57,955 | $12,471 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 86 | 120 | $31,920 | $8,943 | 28.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 27 | 33 | $8,866 | $2,575 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 15 | 15 | $8,410 | $2,048 | 24.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $7,731 | $1,757 | 22.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 18 | 18 | $5,868 | $1,667 | 28.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 21 | 29 | $4,943 | $1,492 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 67 | 260 | $73,580 | $21,643 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 34 | 79 | $40,536 | $9,221 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 114 | $28,988 | $8,587 | 29.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 29 | 30 | $16,991 | $4,824 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $11,902 | $3,305 | 27.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 26 | 26 | $7,999 | $2,229 | 27.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 26 | 34 | $5,606 | $1,857 | 33.1% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2022 | 11 | 13 | $3,150 | $825.52 | 26.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 177 | $50,091 | $14,990 | 29.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 97 | $48,243 | $11,705 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 72 | 116 | $28,441 | $8,982 | 31.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $10,460 | $3,057 | 29.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 14 | 14 | $4,098 | $1,222 | 29.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 21 | 23 | $3,654 | $1,176 | 32.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 77 | 352 | $70,363 | $20,769 | 29.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 88 | 245 | $57,751 | $14,981 | 25.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 39 | 46 | $17,244 | $4,992 | 29.0% |
About Dr. Sairah Ahmed, MD
Dr. Sairah Ahmed, MD is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1144387192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sairah Ahmed, MD has received a total of $99,066 in payments from pharmaceutical and medical device companies, with $42,627 received in 2024. These payments were reported across 101 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($85,354).
As a Medicare-enrolled provider, Ahmed has provided services to 1,064 Medicare beneficiaries, totaling 2,398 services with total Medicare billing of $201,326. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Houston, TX
- Active Since 01/02/2007
- Last Updated 10/16/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1144387192
Products in Payments
- Yescarta (Drug) $36,935
- ADCETRIS (Biological) $3,575
- clonoSEQ (Device) $3,090
- KYMRIAH (Biological) $1,310
- CARVYKTI (Drug) $132.60
- Pomalyst (Drug) $115.85
- MOZOBIL (Drug) $115.57
- Revlimid (Drug) $114.23
- Cresemba (Drug) $107.84
- KYMRIAH (Drug) $85.24
- CARVYKTI (Biological) $73.00
- DARZALEX (Drug) $58.88
- IMBRUVICA (Drug) $29.32
- Epkinly (Drug) $28.36
- JAYPIRCA (Drug) $27.60
- DARZALEX (Biological) $17.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001